AFT confirms demonstration of 24-hour efficacy for Crystawash extend hand sanitiser

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces independent laboratories have found that its new Crystawash Extend Hand Sanitiser:

Displays 24-hour residual efficacy against germs evidenced by testing on synthetic skin1 against S.Aureus and E.Coli2.
Kills 99.99% of germs on immediate contact being S.Aureus, E.Coli, P.aeruginosa, and E. hirae3
Meets the accepted standard for killing Corona virus, evidenced by activity against the Corona virus surrogate [Murine hepatitis virus (MHV1)4

The newly developed, ethanol free, foaming formulation adds to AFT’s existing Crystawash sanitiser range in Australia and New Zealand and meets the huge demand for hand sanitiser that has emerged with the Covid-19 pandemic. It also enhances the appeal of AFT’s over-the-counter portfolio of medicines, now sold in more than 6,000 pharmacies and other outlets across Australasia.

AFT Managing Director Dr Hartley Atkinson said: “Crystawash Extend’s long-lasting protection offers real advantages over many other sanitisers, which are challenged every time a new surface is touched.

“Crystawash Extend covers the hands with an invisible, water-proof, biostatic layer that ruptures the membranes of germs upon contact. The result is effective hand sanitisation and protection against contact of multiple germ-infected surfaces. The chosen formulation was developed after rigorous testing on a number of potential formulations”

Dr Atkinson said AFT believes the product has long-term potential.

“Despite the very welcome advent of several COVID-19 vaccines, we see no let-up in demand for effective hand sanitiser. The vaccination programme will take some time to roll out. And even after the programme has been completed, we expect consumer interest in hand sanitisation to remain strong.”

Dr Atkinson said Crystawash Extend sales will add to this financial year’s results in Australia and New Zealand and also has potential around the world as AFT leverages its global network of partners to out-license the product in other jurisdictions. Already Canada’s CombomedPharma Inc has agreed to distribute Crystawash Extend in that country and more agreements are expected to follow.


  1. VITRO-SKIN®; Florida Suncare Testing, Inc. IMS Division. substrates/vitro-skin
  2. AFT Pharmaceuticals/AsureQuality Laboratory Services, New Zealand microbiological effectiveness study evaluating residual killing activity against transient microbial skin flora on synthetic skin (test organisms: S.Aureus NZRM 147/ATCC 6538 and E.Coli NZRM 2577/ATCC 8739).
  3. Time Kill Test conducted by Eurofins BioPharma Product Testing, Australia; Protocol: TMD-110, EN 13727; Test organisms: S.Aureus ATCC 6538, E.Coli NCTC 10538, P.aeruginosa ATCC 15442, and E. hirae ATCC 10541
  4. Virucidal Test by Carrier Method conducted by Eurofins BioPharma Product Testing, Australia; Protocol: TMCV 006, ASTM E1053; Test organisms: Murine hepatitis virus (MHV1) ATCC/VR-261.

For more information


Dr Hartley Atkinson

Managing Director

AFT Pharmaceuticals

Tel: +64 9488 0232


Richard Inder

The Project

Tel: +64 21 645 643

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website